Belite Bio Inc ADR (BLTE) - Total Liabilities
Based on the latest financial reports, Belite Bio Inc ADR (BLTE) has total liabilities worth $15.48 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Belite Bio Inc ADR - Total Liabilities Trend (2020–2025)
This chart illustrates how Belite Bio Inc ADR's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Belite Bio Inc ADR's working capital to evaluate short-term liquidity relative to the company's equity base.
Belite Bio Inc ADR Competitors by Total Liabilities
The table below lists competitors of Belite Bio Inc ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SDIC Essence Holdings Co Ltd
SHG:600061
|
China | CN¥324.54 Billion |
|
Mohawk Industries Inc
NYSE:MHK
|
USA | $5.41 Billion |
|
Accelleron Industries AG
SW:ACLN
|
Switzerland | CHF1.06 Billion |
|
Definity Financial Corp
TO:DFY
|
Canada | CA$8.90 Billion |
|
B2Gold Corp
TO:BTO
|
Canada | CA$2.25 Billion |
|
Colgate Palmolive (India) Limited
NSE:COLPAL
|
India | Rs-16.64 Billion |
|
AIXTRON SE
XETRA:AIXA
|
Germany | €162.80 Million |
|
Castellum AB
ST:CAST
|
Sweden | Skr80.74 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Belite Bio Inc ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BLTE stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Belite Bio Inc ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Belite Bio Inc ADR (2020–2025)
The table below shows the annual total liabilities of Belite Bio Inc ADR from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.07 Million | +59.56% |
| 2024-12-31 | $6.31 Million | +49.87% |
| 2023-12-31 | $4.21 Million | +51.91% |
| 2022-12-31 | $2.77 Million | -91.71% |
| 2021-12-31 | $33.44 Million | +2.02% |
| 2020-12-31 | $32.78 Million | -- |
About Belite Bio Inc ADR
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and … Read more